Trials / Completed
CompletedNCT05864365
A Biomarker Study of ATH434 in Participants With MSA
An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Alterity Therapeutics · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATH434 | ATH434 taken by mouth two times per day |
Timeline
- Start date
- 2023-05-23
- Primary completion
- 2025-02-26
- Completion
- 2025-02-26
- First posted
- 2023-05-18
- Last updated
- 2025-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05864365. Inclusion in this directory is not an endorsement.